Opus Genetics Inc.
Publicly observedRaleigh, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Raleigh | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Opus Genetics Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | YD2GB4S983V9 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Sept 2026Publicly observed
NIH SBIR/STTR award: Development of OPGx-NMNAT1 as a gene therapy for NMNAT1 associated LCA.
USD 1,012,469.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
- Grant30 Sept 2024Publicly observed
NIH SBIR/STTR award: A single mutation-independent AAV gene therapy for the treatment of autosomal-dominant retinitis pigmentosa.
USD 836,933.00 · National Eye Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.